ZVRA
Zevra Therapeutics, Inc.
Biotechnology
Market Cap$650M
5Y Perf.+270.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ZVRA vs PTCT vs RARE vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$5.35B
5Y Perf.+45.3%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
ZVRA vs PTCT vs RARE vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ZVRA | PTCT | RARE | FOLD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $650M | $5.35B | $2.57B | $4.55B |
| Revenue (TTM) | $122M | $827M | $669M | $634M |
| Net Income (TTM) | $124M | $-187M | $-609M | $-27M |
| Gross Margin | 85.8% | 49.7% | 83.6% | 87.9% |
| Operating Margin | -4.4% | -8.3% | -83.9% | 5.2% |
| Forward P/E | 11.8x | 8.3x | — | 40.6x |
| Total Debt | $63M | $492M | $1.28B | $483M |
| Cash & Equiv. | $62M | $985M | $434M | $214M |
ZVRA vs PTCT vs RARE vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ZVRA
PTCT
RARE
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Zevra Therapeutics,… (ZVRA) | 100 | 370.0 | +270.0% |
| PTC Therapeutics, I… (PTCT) | 100 | 145.3 | +45.3% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZVRA vs PTCT vs RARE vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ZVRA leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Amicus Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. PTCT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ZVRA
Zevra Therapeutics, Inc.
The Growth Play
ZVRA carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 350.9%, EPS growth 159.2%, 3Y rev CAGR 118.8%
- Lower volatility, beta 0.63, Low D/E 40.9%, current ratio 5.68x
- 350.9% revenue growth vs FOLD's 20.0%
- 101.6% margin vs RARE's -91.0%
Best for: growth exposure and sleep-well-at-night
PTCT
PTC Therapeutics, Inc.
The Long-Run Compounder
PTCT is the clearest fit if your priority is long-term compounding.
- 7.3% 10Y total return vs FOLD's 119.2%
- Lower P/E (8.3x vs 40.6x)
Best for: long-term compounding
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 0.63
- Beta 0.63, current ratio 2.84x
- Beta 0.63 vs RARE's 1.42
- +137.9% vs RARE's -21.8%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ZVRA | 350.9% revenue growth vs FOLD's 20.0% |
| Value | PTCT | Lower P/E (8.3x vs 40.6x) |
| Quality / Margins | ZVRA | 101.6% margin vs RARE's -91.0% |
| Stability / Safety | FOLD | Beta 0.63 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs RARE's -21.8% |
| Efficiency (ROA) | ZVRA | 45.6% ROA vs RARE's -45.8%, ROIC -2.9% vs -89.4% |
ZVRA vs PTCT vs RARE vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2025
FY 2025
Segment breakdown not available.
ZVRA vs PTCT vs RARE vs FOLD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLZVRALAGGINGRARE
Who Leads Where
ZVRA leads in 3 of 6 categories
PTCT leads 1 • FOLD leads 1 • RARE leads 0
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
FOLDAmicus Therapeutics, …
1leads
PTCTPTC Therapeutics, Inc.
1leads
ZVRAZevra Therapeutics, I…
3leads
6 Total Categories
CATEGORYLEADERvs PTCTvs FOLDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ZVRA4/6
Valuation MetricsMultiples, price ratios, and targets
PTCT3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ZVRA5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ZVRA3/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ZVRA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PTCT is the larger business by revenue, generating $827M annually — 6.8x ZVRA's $122M. ZVRA is the more profitable business, keeping 101.6% of every revenue dollar as net income compared to RARE's -91.0%. On growth, ZVRA holds the edge at +77.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ZVRAZevra Therapeutic… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $122M | $827M | $669M | $634M |
| EBITDAEarnings before interest/tax | -$3M | -$37M | -$536M | $40M |
| Net IncomeAfter-tax profit | $124M | -$187M | -$609M | -$27M |
| Free Cash FlowCash after capex | $12M | -$229M | -$487M | $30M |
| Gross MarginGross profit ÷ Revenue | +85.8% | +49.7% | +83.6% | +87.9% |
| Operating MarginEBIT ÷ Revenue | -4.4% | -8.3% | -83.9% | +5.2% |
| Net MarginNet income ÷ Revenue | +101.6% | -22.6% | -91.0% | -4.3% |
| FCF MarginFCF ÷ Revenue | +9.8% | -27.7% | -72.8% | +4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +77.5% | -76.8% | -2.4% | +23.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +11.5% | -100.3% | -17.2% | -89.0% |
ZVRA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
PTCT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 8.1x trailing earnings, ZVRA trades at a 2% valuation discount to PTCT's 8.3x P/E. On an enterprise value basis, PTCT's 5.4x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | ZVRAZevra Therapeutic… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $650M | $5.3B | $2.6B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $651M | $4.9B | $3.4B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | 8.15x | 8.29x | -4.48x | -164.85x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.80x | — | — | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 5.42x | — | 114.88x |
| Price / SalesMarket cap ÷ Revenue | 6.11x | 3.09x | 3.82x | 7.17x |
| Price / BookPrice ÷ Book value/share | 4.07x | — | — | 16.29x |
| Price / FCFMarket cap ÷ FCF | — | 7.61x | — | 152.43x |
PTCT leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
ZVRA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ZVRA delivers a 81.3% return on equity — every $100 of shareholder capital generates $81 in annual profit, vs $-6 for RARE. ZVRA carries lower financial leverage with a 0.41x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), PTCT scores 7/9 vs FOLD's 4/9, reflecting strong financial health.
| Metric | ZVRAZevra Therapeutic… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +81.3% | — | -6.1% | -12.0% |
| ROA (TTM)Return on assets | +45.6% | -6.8% | -45.8% | -3.2% |
| ROICReturn on invested capital | -2.9% | — | -89.4% | +5.3% |
| ROCEReturn on capital employed | -2.2% | +55.9% | -46.4% | +5.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.41x | — | — | 1.76x |
| Net DebtTotal debt minus cash | $800,000 | -$492M | $842M | $269M |
| Cash & Equiv.Liquid assets | $62M | $985M | $434M | $214M |
| Total DebtShort + long-term debt | $63M | $492M | $1.3B | $483M |
| Interest CoverageEBIT ÷ Interest expense | 22.02x | -1.67x | -14.49x | 1.00x |
ZVRA leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ZVRA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTCT five years ago would be worth $16,026 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, FOLD leads with a +137.9% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors ZVRA at 30.8% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | ZVRAZevra Therapeutic… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +31.9% | -16.0% | +10.7% | +1.5% |
| 1-Year ReturnPast 12 months | +46.5% | +58.2% | -21.8% | +137.9% |
| 3-Year ReturnCumulative with dividends | +123.6% | +16.1% | -44.5% | +19.0% |
| 5-Year ReturnCumulative with dividends | +15.8% | +60.3% | -77.2% | +48.6% |
| 10-Year ReturnCumulative with dividends | -90.9% | +733.2% | -59.4% | +119.2% |
| CAGR (3Y)Annualised 3-year return | +30.8% | +5.1% | -17.8% | +6.0% |
ZVRA leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ZVRAZevra Therapeutic… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.62x | 1.03x | 1.36x | 0.61x |
| 52-Week HighHighest price in past year | $13.16 | $87.50 | $42.37 | $14.50 |
| 52-Week LowLowest price in past year | $7.16 | $37.94 | $18.29 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +83.6% | +73.7% | +61.7% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 67.7 | 45.3 | 66.6 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.0M | 1.8M | 3.0M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ZVRA as "Buy", PTCT as "Buy", RARE as "Buy", FOLD as "Buy". Consensus price targets imply 131.8% upside for ZVRA (target: $26) vs 0.1% for FOLD (target: $15).
| Metric | ZVRAZevra Therapeutic… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $25.50 | $98.00 | $48.36 | $14.50 |
| # AnalystsCovering analysts | 8 | 26 | 33 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ZVRA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PTCT leads in 1 (Valuation Metrics).
Best OverallZevra Therapeutics, Inc. (ZVRA)Leads 3 of 6 categories
Loading custom metrics...
ZVRA vs PTCT vs RARE vs FOLD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ZVRA or PTCT or RARE or FOLD a better buy right now?
For growth investors, Zevra Therapeutics, Inc.
(ZVRA) is the stronger pick with 350. 9% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Zevra Therapeutics, Inc. (ZVRA) offers the better valuation at 8. 1x trailing P/E (11. 8x forward), making it the more compelling value choice. Analysts rate Zevra Therapeutics, Inc. (ZVRA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ZVRA or PTCT or RARE or FOLD?
On trailing P/E, Zevra Therapeutics, Inc.
(ZVRA) is the cheapest at 8. 1x versus PTC Therapeutics, Inc. at 8. 3x. On forward P/E, Zevra Therapeutics, Inc. is actually cheaper at 11. 8x.
03Which is the better long-term investment — ZVRA or PTCT or RARE or FOLD?
Over the past 5 years, PTC Therapeutics, Inc.
(PTCT) delivered a total return of +60. 3%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: PTCT returned +852. 1% versus ZVRA's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ZVRA or PTCT or RARE or FOLD?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 61β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 123% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Zevra Therapeutics, Inc. (ZVRA) carries a lower debt/equity ratio of 41% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ZVRA or PTCT or RARE or FOLD?
By revenue growth (latest reported year), Zevra Therapeutics, Inc.
(ZVRA) is pulling ahead at 350. 9% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ZVRA leads at 118. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ZVRA or PTCT or RARE or FOLD?
Zevra Therapeutics, Inc.
(ZVRA) is the more profitable company, earning 78. 2% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 78. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ZVRA or PTCT or RARE or FOLD more undervalued right now?
On forward earnings alone, Zevra Therapeutics, Inc.
(ZVRA) trades at 11. 8x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 28. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZVRA: 131. 8% to $25. 50.
08Which pays a better dividend — ZVRA or PTCT or RARE or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ZVRA or PTCT or RARE or FOLD better for a retirement portfolio?
For long-horizon retirement investors, PTC Therapeutics, Inc.
(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +852. 1% 10Y return). Both have compounded well over 10 years (PTCT: +852. 1%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ZVRA and PTCT and RARE and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ZVRA: 77.5% · PTCT: -76.8%)P/E Ratio<
x
(ZVRA: 8.1x · PTCT: 8.3x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.